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Patients in Colombia affected by cutaneous leishmaniasis (CL) face significant geopolitical and 
socioeconomic barriers to accessing diagnosis and treatment. This study aimed to understand 
how the geosocial characteristics of a patient’s area of residence affect time to medical 
consultation and disease status at consultation. An observational cross-sectional study was 
performed of individuals with CL who consulted at a local clinical referral center (CIDEIM) in 
Cali and Tumaco, Colombia. Descriptive, bivariate, and multivariable simple and ordinal logistic 
regression analyses were done to examine how area of residence (urban or rural) and cost of 
transportation to the nearest urban center may influence complexity and time of evolution of the 
disease at first medical visit.  Two separate disease complexity classifications – cplexA and 
cplexB - were created based on factors such as mucosal involvement, lymphatic dissemination, 
and varying number and size of lesions; a composite score of both definitions was also 
constructed. CL Patients who had to pay greater than $60,000 COP for transportation were more 
likely to have a complex disease state at consultation based on the cplexA criteria (aOR = 2.11 
[95% CI: 1.11 – 4.02]) and had higher odds of presenting with more complex disease (ordinal 
logistic regression; aOR = 1.78 [95% CI: 1.09 – 2.92]). A protective association between rurality 
and the time of evolution for the first lesion was also seen, showing that patients who lived in 
rural regions were less likely to have longer wait times before consulting at CIDEIM when 
compared to those who lived in urban centers (aOR = 0.66 [95% CI: 0.45 – 0.97]). High cost of 
transportation to nearby urban centers remains a significant barrier to equitable access of medical 
services for CL patients living in rural Colombia. Additionally, patients with CL in living non-
endemic areas suffer extended time of evolution of the disease before consulting at a local 
referral center, signifying a need for heighted clinical suspicion and services in urban areas.  
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Leishmaniasis is a neglected parasitic disease with a worldwide distribution, mainly affecting the 
impoverished and most marginalized. The global incidence for cutaneous leishmaniasis (CL) is 
estimated at 0.7 to 1.2 million new cases per year (1). CL is endemic in 98 countries worldwide, 
of which Colombia is in the top ten countries with the highest incidence. It is estimated that more 
than 11 million people are at risk for CL in Colombia, with the highest number of cases (52% of 
total cases in 2017) centered in five departments: Antioquia, Santander, Nariño, Tolima and 
Norte de Santander (2). Despite the fact that 77.7% of cutaneous leishmaniasis cases were 
reported in rural areas, the majority of the studies analyzing risk factors focus on biological and 
clinical correlates, often ignoring socioeconomic factors that promote a high disease burden in 
these areas. 
 
CL patients in rural Colombia face significant geographical, political and economic barriers to 
securing high-quality diagnosis and treatment, often due to high income inequality and the threat 
of violence from armed conflict (1,3,4). Access to care is a prevailing health issue in terms of 
rural health, especially in developing countries (5,6). Previous research recognizes distance and 
available transportation as barriers to accessing high-quality health services but other studies 
have provided contradictory findings on how distance from healthcare access affects disease 
prevention and treatment (5–8). Increased distance from health centers has shown to be 
associated with increased delay from onset of symptom to diagnosis (9–11). Diagnostic delay has 
also been shown to be associated with increased complexity of infectious disease pathogenesis, 
providing a potential mechanism through which increased distance from a health center can act 
as a barrier to health (12–15). These findings, however, while spanning both rural and urban 
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regions, focus mostly on healthcare utilization in a general disease context, making the results 
difficult to extrapolate to CL in Colombia, for which there is a clear dearth of research into the 
social drivers of the disease.   
 
Few studies have looked at how rurality and transportation affect patterns of healthcare access 
for these patients in Colombia, or even in Latin America more broadly (16–19). A mixed-
methods study on CL and gender in the country found that, due to the low fatality of the disease, 
individuals living in remote, rural regions feel unmotivated to seek medical care unless the 
disease rapidly progresses (11). Individuals with CL living in remote regions also seem to first 
try home herbal remedies or antibiotic creams acquired from a local pharmacy before even 
considering consulting at a clinic (3,11). One major shortcoming of the literature, however, is 
that previous studies focus solely on time of evolution of this disease in either rural or urban 
communities independently but have not sought to evaluate how an individual’s area of 
residence is associated with time of evolution or complexity of disease at consultation. 
Additionally, previous studies have used rurality solely as binary – rural or non-rural – but have 
yet to further explore if their findings are consistent regardless of how far an individual in a rural 
area lives from an urban center. 
 
The current study evaluates how the area of residence – urban or rural - and cost of 
transportation, a proxy for distance, from the patient’s community to the nearest urban center 
may act as a barrier to health, potentially influencing time from onset of symptoms to 
consultation at a local referral diagnostic center and complexity of disease, with the hope of 
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Study Design and Area 
This cross-sectional study was conducted by drawing from a database of clinical records of 
patients diagnosed with CL between January 2012 and April of 2018 at the clinical referral 
centers of the Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM) in 
Tumaco and Cali (20).  
Study Sample 
Patients who met the following eligibility criteria were included: male and female individuals of 
any age with a confirmed diagnosis of cutaneous leishmaniasis and a date of initial consultation 
during the study period.  Patients with an incomplete clinical history particularly regarding 
confirmed Leishmania diagnosis or lesion characteristics were excluded.  
 
Outcome Variables: 
Complexity of Disease at Diagnosis 
 
We are interested in cost of transportation and rurality as potential barriers that may lead to 
diagnostic delay and more complex disease presentation at consultation. To capture disease 
complexity, we created two variables based on factors such as mucosal involvement, lymphatic 
dissemination, and varying number and size of lesions. For the cplexA, the following criteria had 
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to be satisfied to classify the case as mild: no greater than one lesion, no lesion greater than three 
centimeters in diameter, no evidence of lymphatic dissemination, and no evidence of muco-
cutaneous lesions. For cplexB, we classified an individual’s disease as mild if it met the 
following criteria: no greater than four cutaneous lesions, no lesion greater than 5 cm in 
diameter, no evidence of lymphatic dissemination, and no evidence of muco-cutaneous lesions. 
If the above-mentioned criteria were not met, the individual was classified as having more 
complex disease. These two variables are loosely informed by, but not adherent to, the treatment 
guidelines issued by the World Health Organization (WHO) and the Pan-American Health 
Organization (PAHO), by including those criteria related to disease complexity and excluding 
those that were related to viability and safety of local treatment. Both the presence of 
mucocutaneous lesions and evidence of lymphatic dissemination were added as they are 
characteristic of more complex CL in the Americas (23). Given that the criteria for cplexB 
presents a more conservative definition of complexity in which an individual cannot be classified 
as more complex without first also being designated as more complex under the cplexA criteria, 
we also created a three-level complexity variable as follows: mild, more complex only under 
cplexA, more complex by both cplexA and cplexB criteria.  
 
Time of Evolution 
 
An extended time of evolution has been demonstrated to have a positive correlation with a more 
complex pathology of visceral and cutaneous leishmaniasis globally (24). Time of evolution was 
defined as the time from patient-reported symptom onset until consultation at CIDEM. Given 
that the times of evolution are concentrated on the lower time scale (more than 50% report less a 
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time of evolution less than 2 months) and that our primary objective was to understand barriers 
to health access and not evaluate the natural history of the disease, time was operationalized into 
a four-level variable: less than 1 month, between one and up to two months, between two and 
three months, and greater than three months since the onset of symptoms.  
 
Primary Independent Variables: 
Area of Residence: 
The area of residence of each patient was categorized as either urban or rural based on self-
report.   
 
Distance and Cost: 
Given that a significant portion of the patient population resides in rural areas and that the 
geographical information regarding the veredas (a territorial subdivision focused primarily in 
rural areas ) in Colombia is limited, estimates of distance through GIS information or straight-
line Euclidean distances are unavailable. In their place, we used the estimated cost of 
transportation from every vereda to the urban center where each patient received their initial 
diagnosis of CL under the assumption that higher costs of transport are associated with a greater 
distance or travel time. Additionally, given that variety of transportation methods, including 
water- and land-based transport, used to get from rural to urban areas, cost of transportation may 
more accurately capture the true financial burden of seeking timely care as compared to a 
straight-line estimation. For patients’ cost of transportation, we used values recently calculated 
by Berger et al (25), which were based on local health care providers’ knowledge of 
transportation options and costs. Given the monetary denominations of Colombia, the cost of 
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transportation was then operationalized into a three-level variable: less than 20,000 COP, 
between 20,000 and 60,000 COP, and greater than 60,000 COP. 
Sociodemographic and Clinical Factors 
Given that the immune response is dependent on or can be influenced by various 
sociodemographic and clinical factors (11,26), age, sex, race, insurance type, occupation, history 
of previous cutaneous lesions, presence of comorbidities, and parasite species were analyzed as 
covariates.  
Statistical analysis 
We used simple descriptive statistics to describe the sociodemographic and clinical 
characteristics of the sample. We then examined the bivariate associations between each of our 
two primary independent variables of interest (urban/rural area of residence and cost of 
transportation) and each of the outcomes of interest (cplexA, cplexB, the composite measure of 
complexity, and time of evolution) using χ2 tests. For each of the two dichotomous outcomes 
(cplexA and cplexB), we further used logistic regression analysis to quantify the unadjusted and 
adjusted associations with both area of residence and transportation cost. For the two ordinal 
outcomes (the 3-level composite measure of complexity and the 4-level time of evolution 
variable), ordered logistic regression analysis was performed. To control for potential 
confounders, each multivariable model included all sociodemographic and clinical variables that 
were associated with the respective outcome variable at the 0.20 alpha level. All analyses were 




Among the 982 individuals that consulted at CIDEIM between January 2012 and April 2018 and 
had a laboratory-confirmed diagnosis of cutaneous leishmaniasis, 710 individuals had 
information on their area of residence (urban versus rural), and 315 individuals had enough 
detailed information regarding their address and vereda to estimate cost of transportation to their 
CIDEIM referral center (25). The sociodemographic and clinical characteristics of each analytic 
sample are presented in Table 1.  
 
Table 1: Sample Characteristics 
 
All patients with a positive 
confirmed laboratory 
diagnosis of CL (N = 982) * 
Patients with complete 
information about region 
of residence (N = 710) * 
Patients with complete 
neighborhood and cost of 
transportation data (N = 315) * 
Characteristic n (%) or mean (SD) n (%) or mean (SD) n (%) or mean (SD) 
Age in years (in     
years) 
30.7 (16.4) 30.4 (16.4) 28.3 (15.9) 
Male 753 (76.7) 549 (77.3) 244 (77.5) 
Afrodecendent  456 (46.4) 313 (44.1) 121 (38.4) 
Public Insurance 692 (70.5) 520 (73.2) 220 (69.8) 
Work in Agriculture 495 (50.4) 391 (55.1) 184 (58.4)  
Presence of 
Comorbidities 
262 (26.7) 168 (23.7) 57 (18.1) 
History of Previous 
Lesion  
83 (8.5) 50 (7.1) 19 (6.0) 
L.V. panamensis † 211/253(83.6) 125/156 (80.1) 71/82 (86.6) 
Live in Rural Area 576 (58.7) 576 (81.1) 223 (70.8) 
* Numbers may not sum to total due to missing data 
† (n/N) - given that species identification is resource-intensive, it is only available for the patients that participated in 
clinical trials and thus a high percentage of the sample has missing species data 
 
The individuals with information regarding their area of residence were similar to the overall 
patient population. They had an average age of 30.4 years. Five hundred forty-nine were male 
(77.3%) and 44.1% identified as Afro-descendant. The majority of individuals worked in 
agriculture (55.1%), lived in a rural area (81.1%), had public insurance (73.2), and were infected 
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with Leishmania (Viannia) panemensis (80.1% out of those that had undergone species 
identification). Additionally, 7.1% reported a history of previous skin lesions and 23.7`% had a 
clinical comorbidity.  
 
Patients for whom we had estimates of transportation costs had a mean age of 28.3 years and 
were majority male (77.5%), had public insurance (69.8%), lived in a rural area (70.8%) and 
were infected with L. panamensis (86.6% out of those that had undergone species identification). 
One hundred twenty-one individuals identified as afro-descendent (38.4%), 58.4% worked in 
agriculture, 6.0% reported a history of previous skin lesions and 18.1% had a clinical 
comorbidity. 
 
Unadjusted and adjusted associations of both area of residence and cost of transportation with 
complexity of disease based on cplexA criteria are shown in Table 2. Overall, 74.6% of patients 
were categorized as having more complex disease at initial consultation based on this definition. 
Having to pay more than $60,000 COP for transportation from a patient’s vereda of residence to 
the nearest urban center was associated with a significantly higher odds of being classified as 
more complex compared with those who had to pay less than $20,000 COP (unadjusted OR = 
1.91 [95% CI: 1.04 – 3.49]). The significant association persisted even after adjusting for 
potential cofounders (adjusted OR = 2.11 [95% CI: 1.11 – 4.02]. Rural residence was associated 
with lower odds of more complex disease at diagnosis; however, the association was not 




Table 2: Association of Area of Residence and Cost of Transportation with Disease Complexity based cplexA 
Criteria 
 N  
n (%) with more complex 
cutaneous leishmaniasis based on 





Area of Residence (N = 700)         
Urban  130 101 (77.7) REF   REF   
Rural 570 398 (69.8) 0.67 (0.42, 1.04) 0.65 (0.40, 1.05) 
Cost of Transportation in 
Colombian Pesos (N = 314) 
        
< 20,000  155 105 (67.7) REF   REF   
20,000 - 60,000  64 40 (62.5) 0.79 (0.43, 1.46) 0.89 (0.46, 1.71) 
>60,000 95 76 (80.0) 1.91 (1.04, 3.49) 2.11 (1.11, 4.02) 
* Adjusted for race, sex, presence of comorbidities, and history of a previous lesion for Area of Residence model 
(N = 664); Adjusted for age, sex, and the presence of comorbidities for Cost of Transportation model (N = 301)  
 
As shown in Table 3, 35.9% of patients were categorized as more complex at initial consultation 
using the cplexB criteria. Patients with transportation costs of less than $20,000 COP were the 
least likely to be diagnosed with more complex disease; however, the association between 
greater costs and cplexB-defined disease complexity did not reach statistical significance, nor did 
the association between rural residence and lower odds of more complex disease.  
 
Table 3: Association of Area of Residence and Cost of Transportation with Disease Complexity based on cplexB 
Criteria 
 N 
n (%) with more complex cutaneous 





Area of Residence (N = 694)         
Urban  129 53 (41.1) REF   REF   
Rural 565 192 (34.0) 0.74 (0.50, 1.09) 0.75 (0.50, 1.14) 
Cost of Transportation in 
Colombian Pesos (N = 309) 
        
< 20,000  152 37 (24.3) REF   REF   
20,000 - 60,000 63 20 (31.8) 1.45 (0.76, 2.76) 1.44 (0.77, 2.70) 
>60,000 94 28 (29.8) 1.32 (0.74, 2.35) 1.52 (0.76, 3.01) 
* Adjusted for race and the presence of comorbidities for Area of Residence model (N = 661); Adjusted for age, 




Crude analyses showed that individuals with a rural residence and those with transportation costs 
less than $20,000 COP were the least likely to be diagnosed with more complex disease but the 
association was not significant at the 0.05 level (Table 4). After adjusting for covariates, 
however, individuals who had to pay an estimated cost of transportation greater than $60,000 
COP were found to have a significantly higher odds of having more complex disease than those 
individuals who have to pay less (adjusted OR = 1.78 [95% CI: 1.09 – 2.92]).   
 
Table 4: Association of Area of Residence and Cost of Transportation with Composite Complexity Score 
 N 
n (%) who had 
a low 
complexity  
n (%) who had 
a moderate 
complexity  







Area of Residence 
(N = 694) 
          
Urban  129 29 (22.5) 47 (36.4) 53 (41.1) REF   REF   
Rural 565 172 (30.4) 201 (35.6) 192 (34.0) 0.71 (0.50, 1.01) 0.72 (0.50, 1.05) 
Cost of 
Transportation in 
Colombian Pesos (N 
= 308) 
          
< 20,000  152 50 (32.9) 65 (42.8) 37 (24.3) REF   REF   
20,000 - 60,000 63 24 (38.1) 19 (30.2) 20 (31.6) 1.04 (0.60, 1.79) 1.22 (0.69, 2.15) 
>60,000 93 19 (20.2) 47 (50.0) 28 (29.8) 1.54 (0.95, 2.49) 1.78 (1.09, 2.92) 
* Ordinal logistic regression; Adjusted for sex, race, and the presence of comorbidities for Area of Residence 
model (N = 661); Adjusted for sex and the presence of comorbidities for Cost of Transportation model (N = 297)  
 
  
Table 5 shows the unadjusted and adjusted associations of both area of residence and cost of 
transportation with time of evolution of the patient’s first lesion. Living in a rural area was found 
to be associated with a 35% decreased likelihood of having a longer time of evolution when 
compared with those who lived in urban areas (unadjusted OR = 0.65 [95% CI: 0.46– 0.92]), and 
the protective effect persisted after controlling for potential confounders (adjusted OR = 0.66 
[95% CI: 0.45 – 0.97]). Individuals who had to pay less than $20,000 COP for transportation 
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were found to be the least likely to have a higher time of evolution, but the association did not 
reach statistical significance.  
 
 
Upon stratifying the results by the two cities where CIDEIM is present, Cali and Tumaco, the 
aforementioned effects remained consistent – an apparent association between increased disease 
complexity and higher cost of transportation and a protective association between rurality and 
time of evolution), especially for Tumaco where the majority of the patients in our sample sought 




Table 5: Association of Area of Residence and Cost of Transportation with Time of Evolution 
 N 
n (%) who 






n (%) who 
had a time 
of evolution 




n (%) who 
had a time 
of evolution 




n (%) who 
had a time 
of evolution 






Adjusted* OR (95%) 
Area of 
Residence (N = 
699) 
           
Urban  134 15 (11.2) 33 (24.6) 44 (32.8) 42 (31.3) REF   REF   




Pesos (N = 308) 
           
< 20,000  152 6 (4.0) 81 (53.3) 45 (29.6) 20 (13.2) REF   REF   
20,000 - 60,000 63 2 (3.2) 27 (42.9) 19 (30.2) 15 (23.8) 1.63 (0.95, 2.82) 1.36 (0.73, 2.56) 
>60,000 93 7 (7.5) 36 (38.7) 29 (31.2) 21 (22.6) 1.48 (0.91, 2.40) 1.38 (0.77, 2.50) 
* Ordinal logistic regression; Adjusted for age, race, sex, work, insurance, and the presence of comorbidities for the Area 
of Residence model (N = 645); Adjusted for age, sex, race, insurance, and the presence of comorbidities for the Cost of 




Using data from a local clinical referral center (CIDEIM) in southwest Colombia, this study 
found that there was a positive association between cost of transportation from a patient’s vereda 
to the nearest urban center and an increased likelihood of more complex cutaneous leishmaniasis 
at first clinical consultation. CL Patients who had to pay greater than $60,000 COP for 
transportation were more likely to be classified as having more complex disease based on the 
cplexA criteria and had higher odds of presenting with more complex disease. Contrary to our 
expectation, however, a protective association between rurality and the time of evolution for the 
first lesion was also seen, showing that patients who lived in rural regions were less likely to 
have longer wait times before consulting at CIDEIM when compared to those who lived in urban 
centers. While not statistically significant, a similar protective association between rurality and 
complexity was seen, where patients living in a rural residence were less likely to be diagnosed 
with more complex disease when compared to those with urban residence.  
 
While previous studies have attempted to understand barriers to CL diagnosis in rural regions of 
Latin America (11,17,27,28), to our knowledge, the current study is the first to examine how 
distance from an urban center, here estimated through cost of transportation, is associated with 
time of evolution and complexity of disease at first visit to a local CL referral clinic. We uncover 
a threshold effect, in which we only see a significant association between cost of transportation 
and complexity of disease when patients need to pay greater than $60,000 COP. Assuming that 
high cost is associated with either farther distances away from the urban center or a more 
expensive mode of transportation (i.e. marine vs land transport), our results highlight that 
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transportation is still a significant barrier to equitable health access in individuals living in rural 
Colombia.  
 
Interestingly, while we see a significant association with cost of transportation and complexity 
using the cplexA criteria, the association using cplexB guidelines did not reach statistical 
significance. A consistent trend, however, is still seen throughout: patients with less than 
$20,000 COP in transportation costs have the lowest odds of being diagnosed with more 
complex disease. Given that cplexB gives a more conservative definition of complexity, the cases 
identified using this criterion are implied to be of high complexity while the cplexA criteria 
captures moderate disease as well. The observed difference in statistical significance might be 
explained through this differential complexity classification: individuals with moderate disease, 
(cplexA) might not be motivated to consult a referral clinic at the nearest urban center if their 
cost of transportation exceeds $60,000 COP but individuals with more complex CL (cplexB) 
would be more willing to seek diagnosis and treatment, regardless of the cost. Ordinal logistic 
regression of the complexity score created as a composite of both criteria revealed that CL 
patients that had transportation costs that exceeded $60,000 COP had higher odds of being more 
complex at time of consultation, supporting the idea that mostly individuals with more complex 
disease would be willing to seek diagnosis and treatment despite the high cost.  
 
Despite the few numbers of articles on CL and time of evolution, the majority of the literature 
mentions rurality and associated factors – low trust in medical institution, the use of alternative 
or home remedies, lack of urgency due to the non-fatal nature of the disease, the need for 
multiple, costly hospital visits for treatment – as strong contributors to the high time of evolution 
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seen in Colombian CL patients (11,17,27,29). The current study presents a contradictory 
perspective: compared to those patients living in urban centers, patients living in rural areas had 
significantly lower odds of longer evolution times for their first lesion. Similarly, patients living 
in a rural residence were also less likely to be diagnosed with more complex disease, although 
the association did not reach statistical significance. Given that the majority of CL cases occur in 
rural regions and that in Colombia the disease is often pejoratively associated with remote 
guerilla militants, urban centers are viewed as non-endemic regions for CL. While endemic areas 
bare a higher disease burden, the lack of health professionals trained in a particular disease 
diagnostic or the lack of clinical suspicion in non-endemic regions has shown to be associated 
with increased diagnostic delay (30–33). Thus, in Colombia, individuals in urban centers might 
be susceptible to diagnostic delay and longer times of evolution due to lack of clinical suspicion 
of the disease in non-endemic regions of the country.  
 
While CL is primarily considered a rural disease as infection usually occurs through zoonotic 
transmission from either canine or sylvatic reservoir hosts, rapid deforestation and urbanization 
in Latin America is bringing many people into contact with zoonotic Leishmania hosts and with 
Phlebotomus sand flies (the insect vector for CL) (34). In Colombia, both rapid urbanization and 
forced human migration as a result of armed conflict and drug trafficking has promoted an 
increase in CL cases in the country (4). As cities continue to expand into previously forested 
regions, the country may see an increase in CL cases in urban centers. Given the results of this 
study, local governments and health departments may need to expand clinical diagnostic capacity 
in order to prevent significant diagnostic delays.  
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Interestingly, despite longer time of evolution being associated with higher disease complexity 
(15,35,36), the current study fails to find a significant association between area of residence and 
CL complexity at time of consultation, regardless of the guidelines used to classify the disease as 
complex. The potential reasons – both clinical and social – are many, given the multiple risk 
factors that may influence disease progression (15,26,28). Given that the outcome of CL is 
highly dependent on the host’s immune system (23,37), however, one potential explanation 
might be higher prevalence of malnutrition, which has been shown to suppress the immune 
system and promote lesion persistence (38–41), in patients living in rural areas compared to 
those living in urban centers (42,43). Malnutrition might be modifying the association between 
area of residence and complexity but careful additional investigation is needed.  
 
This study had the following limitations. Due to the lack of geographical information and clear 
political definitions of veredas, neither straight-line Euclidean distance nor distance of roads 
traveled could be determined. Since neither distance travelled nor direct costing of transportation 
is routinely collected from patients, we had to approximate distance from each vereda to the 
nearest urban center using estimated travel costs found in Berger et al (25). While these estimates 
fail to account for variability in transportation methods, differences in routes, and individual 
variation, the approximate transportation costs were estimated by healthcare professionals using 
local knowledge and experience and are thus considered to be highly informed on the basis of 
preferred route, diversity of mode of transportation, and local variation in costs. In regards to the 
outcome variables, currently, to our knowledge, there is no validated complexity score for 
cutaneous leishmaniasis. In order to quantify complexity, however, we used the treatment 
guidelines for local therapy set by PAHO and the WHO as a general starting point, with some 
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notable distinctions. We only included those criteria related to disease complexity and excluding 
those that were related to viability and safety of local treatment. For example, both the WHO and 
PAHO count lesions on the face and joints as ineligible for local treatment. Given that this 
consideration is due to the potential risk of complication from local therapies such as 
thermotherapy and cryotherapy at these locations and not with complexity or chronicity, we 
decided to exclude them from the criteria. A similar rationale was applied with the criterion for 
availability for follow- up. Since the Leishmania species found in Colombia are also capable of 
inducing mucocutaneous lesions as well as capable of disseminating through the lymphatic tract, 
both presence of mucocutaneus lesions and lymphatic dissemination were included as part of the 
complexity criteria. We created a complexity score by combining the two criteria as a substitute 
for a validated score but confirmatory evaluations should be done if a validated scale is created. 
Additionally, only 347 individuals in our sample had undergone testing for parasite species 
identification due to the time-intensive methodology and high cost. Despite this limitation, we 
found no significant association of complexity or time of evolution with parasite species, even 
when accounting for the missing data as an additional category in the variable. In the individuals 
that did have information regarding parasite species, we found that greater than eighty percent 
were infected with L. panamensis, which matches with the observed species distribution found 
throughout the country (2). In addition to cost of transportation, there exist many different factors 
that might influence an individual’s willingness to seek medical attention and ease of transport, 
including remoteness, different modes of transportation, lack of roads, violence, drug trafficking, 
etc. Future studies should work to uncover and address the other equally important influences 
that act as barriers to equitable health for patients in rural Colombia. This research is also an 
observational cross-sectional study using routine clinical data not specifically collected for the 
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purpose of this investigation, meaning that causality cannot be inferred. Additionally, the quality 
of self-reported variables could not be verified.  
 
While the current study examines cost of transportation as it relates to time of evolution and 
complexity at first medical visit, transportation cost should also be examined in relation to 
treatment access, delay, and adherence for CL patients in rural regions. The current standard of 
care for CL is a twenty-day injection regimen with meglumine antimoniate that requires the 
patients to visit a clinic daily. A recent study conducted by Berger et al. (25) estimated that the 
mean cost-per-cure from a patient perspective was $443 USD due to transportation, food, 
lodging, medical and child care, which represents a significant cost given the monthly minimum 
wage of about $260 USD (44). Future studies should address how a higher cost of transportation 
might affect a patient’s willingness to seek and remain on treatment with meglumine antimoniate 
and potentially with miltefosine, an equally efficacious oral medication that has recently been 
incorporated into the standard of care in Colombia after being shown to be a potential alternative 
(45,46).  
 
In conclusion, our analysis revealed that a high cost of transportation to an urban center is 
associated with increased likelihood of higher disease complexity at the time of first consultation 
at a local referral center for patients with CL in rural Colombia. Our findings further demonstrate 
that CL patients living in urban regions often present a higher time of evolution for the disease 
and more complex disease at consultation, setting the basis for future research into the potential 
causes for this phenomenon and underscoring the need for higher clinical suspicion and 
diagnostic capabilities in rapidly-urbanizing regions currently classified as non-endemic for CL. 
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Our study highlights that transportation in rural regions still remains a significant barrier to 
equitable health access for CL patients in Colombia and warrants further investigation into 
interventions that might improve diagnostic and treatment services for these individuals and 
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